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ABSTRACT 
 
This paper explores the extent to which adoption of the Global Reporting Initiative’s G3 reporting 
framework makes the external reporting of a company’s financial, environmental and social 
performance more comparable. This inquiry takes the form of analyzing the content of the 
published sustainability reports of well-known companies to compare and contrast the information 
communicated in these reports.  Particular attention will be paid differences in the published 
content of the second round of G3 reports between companies in the pharmaceutical industry.  
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INTRODUCTION 
 
inancial success has long been accepted as the primary objective of corporate existence. However, 
many social critics have questioned whether financial success is enough. There are increasing 
demands that companies be good corporate citizens as well. Organizations struggle to tell their 
stories, to communicate the good (and sometimes the bad) that they do in the marketplace, in the community, to and 
for the environment, and in society. Quite clearly, the challenge of telling the company’s story is not being met by 
current corporate reporting practices. In particular, criticism has been directed at the failure of annual reports or 
other regulatory files to tell anything about a company's environmental and social performance. Triple bottom-line 
(TBL) reporting, a term coined by John Elkington in his 1997 book Cannibals with Forks: the Triple Bottom Line of 
21st Century Business, aims to remedy this shortcoming by explicitly considering not only the economic 
performance of a firm but also the company’s environmental and social performance as well. An increasingly 
popular practice is the issuance of a corporate responsibility or sustainability report. The international accounting 
firm KMPG reviewed the disclosures of more than 2,200 companies, including the Global Fortune 250 and 100 
largest companies in 22 countries. The KPMG International Survey on Corporate Responsibility Reporting (2008) 
found that 74 percent of the top 100 U.S. companies (as measured by revenue) published corporate responsibility 
information in 2008, either as part of their annual financial report or as a separate document. This was an increase 
from the 37 percent of top U.S. companies that KPMG surveyed in 2005. An even higher percentage of top 
international firms are reporting on their environmental and social performance with 80 percent of the Global 
Fortune 250 companies now releasing this information. 
 
Despite this impressive increase in the issuance of sustainability reports, initial efforts at TBL reporting 
have been plagued by their lack of uniformity, consistency, and comparability in the information presented. The 
Global Reporting Initiative (GRI) has attempted to fill this void by developing a detailed framework that is intended 
to create an analog to the generally accepted accounting principles (GAAP) approach to financial reporting.  Simply 
put, if companies use the same ground rules in preparing their sustainability reports, the information presented in 
those reports should promote greater comparability. This paper considers whether the use of the GRI G3 Framework 
does indeed make TBL reporting more comparable.  In particular, it looks at the evolution of sustainability reporting 
through successive iterations of G3 reports. 
 
F 
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The G3 Guidelines 
 
Formed in 1997, the Global Reporting Initiative (GRI) clearly states its objective: 
 
To enhance responsible decision making by promoting international harmonization in reporting relevant and 
credible corporate economic, environmental, and social performance information (GRI, 2002). 
 
To this end, the GRI has developed and published reporting guidelines which follow the broad TBL 
reporting of economic, environmental, and social performance with the social grouping being further subdivided in 
terms of labor practices, human rights, society, and product responsibility. In an attempt to enhance comparability 
and auditability, the GRI issued its third generation (G3 Guidelines), in October 2006. The G3 framework modifies 
the 97 “key performance indicators” (KPIs) of the G2 framework into 79 performance indicators (GRI, 2007). Fifty 
of these indicators are considered “core” because the GRI believes them to be of interest to most stakeholders and, 
consequently, they are “assumed to be material unless deemed otherwise on the basis of the GRI Reporting 
Principles” (GRI, 2006). One of the most significant aspects of these indicators is that some are quantitative (e.g. 
LA1: Total workforce by employment type, employment contract, and region) while others are qualitative (e.g. EC7: 
Procedures for local hiring and proportion of senior management hired from the local community) in nature. 
Furthermore, the quantitative indicators are expressed in various monetary and non-monetary units of measure.  
 
In addition to these performance indicators, all G3 reports must contain a GRI Content Index (Element 
3.12) to alert readers to where in the sustainability report the standard disclosures can be found (GRI, 2006, p. 22). 
Furthermore, the organization should disclose the level of reporting it has chosen. The levels of reporting range from 
A through C. The GRI’s rationale behind allowing differing levels of reporting is to encourage companies to ease 
their way into using the guidelines, even if they are not prepared to implement all the guidelines immediately. The 
level of reporting chosen can simply be self-declared, verified by an external third party, or checked by the GRI 
itself. Externally verified reports add a “+” to their level of reporting. 
 
In response to criticism of the GRI’s one-size-fits-all approach, the GRI has developed fifteen Sector 
Supplements for segments such as the apparel and footwear, financial services, and automotive industries. [See, for 
example, the GRI Automotive Sector Supplement (GRI, 2004) and the GRI Financial Services Supplement (GRI, 
2009b).] These Sector Supplements are not intended as a replacement for the more general G3 framework but do 
address the more specific issues encountered by companies in particular industries.  
 
While compliance with the Guidelines is entirely voluntary, more than 1,100 reports were officially 
registered with the GRI in 2009 (Ceres, 2010). More than three-quarters of the G250 and nearly 70 percent of the 
N100 use the GRI Guidelines for their reporting (KPMG, 2008) with the number of companies adopting the G3 
guidelines increasing by 46% in 2008 (GRI, 2009a). Further evidence of the dominance of the GRI Guidelines can 
be found by the fact that 64% of companies listed on Germany’s DAX 30, 48% of those listed on France’s CAC 40, 
and 22% of the UK’s FTSE 100 say they use the GRI guidelines (Ceres, 2010). 
 
METHODOLOGY 
 
This study takes the form of analyzing the content of the published sustainability reports of well-known 
companies to compare and contrast the information communicated in these reports. Content analysis is particularly 
appropriate for sustainability disclosures. Pedrini (2007) uses content analysis to investigate the points of 
convergence between intellectual capital and corporate responsibility reports prepared under the GRI’s 2002 
Guidelines. Clarkson et al (2008) develop a content analysis index to test the environmental disclosure under the 
2002 Guidelines.  
 
Sherman (2008; 2009) expands beyond the GRI’s recommended environmental and intellectual capital 
disclosures and examines the extent to which companies present the kind of information that the G3Guidelines 
recommend for all aspects of an organization’s TBL performance. He found difficulty in comparing the information 
presented in the first wave of G3 Reports of Ford and Volkswagen in the automotive industry, Citigroup and 
Barclays in financial services, Merck and Bayer in pharmaceuticals, and Nike and Adidas in the sporting goods 
industry (Sherman, 2009). 
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As a first step, this study looks at the progression of reporting by these eight companies in their second or 
third iteration of G3 reports. The particular companies studied are selected quite intentionally. First of all, these are 
highly visible companies. More significantly, all have reputations for being good corporate citizens and have 
received awards and other recognition for the reporting of their non-financial performance. All prepare sustainability 
reports using the G3 Guidelines. Given these common characteristics, one would expect a greater comparability 
between and among the companies which is one of the paramount goals of the G3 Guidelines. Indeed, one of the 
greatest challenges in evaluating the value that is being added by the content in these disclosures is the 
extraordinarily wide variability in the form of the disclosures.  
 
While variability in the content of the disclosures is expected due to the differing materiality of issues 
which a company faces, one would expect less variability in content from companies operating in the same industry. 
In other words, those companies operating in the same industry face similar challenges to their corporate 
responsibility. To explore this aspect further, this study focuses on the G3 reports of companies in the 
pharmaceutical industry. 
 
Some important differences in the companies’ TBL disclosures may also be expected related to the 
company’s geographic base. There is a general perception that European-based companies are more sensitive to 
issues of sustainability than are U.S.-based organizations. Indeed, the GRI found that of the more than 1,500 
sustainability reports of which it is aware, 49% were issued by European companies.  North American companies 
represent only 14% (GRI, 2009). Consequently, it will be interesting to see if this perception is confirmed by the 
reporting of European companies as compared and contrasted to that of American firms. 
 
After considering the progress (or lack thereof) of the eight companies, spanning four industries, this 
analysis will take a closer look at the measure used by companies in the pharmaceutical industry. By looking at 
some of the more objective G3 performance indicators, a better understanding of the comparability of disclosures 
can be achieved. 
 
ANALYSIS 
 
Ford vs. Volkswagen 
 
Ford and Volkswagen share the same challenges to their responsible corporate citizenship that other 
companies in the automotive industry face. The primary issue is that of greenhouse gas emissions and how the cars 
and trucks they manufacture contribute to climate change. One would therefore expect Ford and Volkswagen to set 
similar goals, follow aligned approaches, and report comparable data. These expectations are disappointed.  
 
Both companies have reported at the A level in their first two G3 reports. While both companies now 
disclose information on 90% of the core performance indicators, there are discrepancies between which indicators 
are reported. In their first G3 reports, issued for 2007, Ford and VW reported on 70% common indicators (Ford, 
2008b; VW, 2008). This improved to 82% in their second iterations for 2009 (Ford, 2010b; VW, 2010). This 
improvement should lead to greater comparability. However, even when a common goal is stated (e.g. reduction of 
CO2), the scale of the reduction is not comparable. While Ford states it plans to reduce the CO2 emissions of its new 
US and EU vehicles by 30% by 2020 (Ford, 2008a, p. 3), Volkswagen does not set CO2 goals for its US or EU 
vehicles, but targets a 20% reduction in fuel use and CO2 emissions in China (Volkswagen, 2008, p.74).  
Interestingly, the greatest divergence of disclosure between the two companies is in the core environmental 
performance indicators. As noted above, Ford discloses some information (partial or complete) for 16 of the 17 for 
both years; VW discloses information on 12 in its 2007 report; on 15 in 2009. Particularly in their first G3 reports, 
the companies are not even disclosing the information on the same indicators. Six of the environmental indicators 
are reported by one company but not the other, leaving 11 common indicators on which some information is 
provided. Given that both companies use the same G3 Guidelines and both companies report at the A level, this is 
particularly disappointing. One would and should expect greater comparability. Based upon the G3 disclosures, it is 
impossible to conclude which company is performing more responsibly in addressing the critical challenge to its 
industry. 
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Citigroup vs. Barclays 
 
Given the B level of reporting chosen by both Citigroup and Barclays, the relatively lower level of 
disclosure is expected when compared to the A level sustainability reports issued by Ford and VW. Following the 
GRI’s rationale in allowing these different reporting levels as a way to ease into the G3 Guidelines, one would hope 
that in future years, the companies would increase their TBL reporting to encompass more information about their 
non-financial performance. That notwithstanding, because both Citigroup and Barclays report at the same level, a 
meaningful comparison of the reports should be possible. While both companies now report on 40% of the total core 
performance indicators (Citigroup, 2009; Barclays, 2009), the comparability of the two banks is impaired by the fact 
they only disclose information on 26% of the same indicators in their first G3 reports (Citigroup, 2008b; Barclays, 
2008c). This drops to 20% in their second G3 reports (Citigroup, 2009; Barclays, 2009). 
 
The issue that received the most discussion in the Citi’s first G3 report is the environment.  Therefore, it is 
not surprising that Citi provides information on twice as many of the G3 environmental core indicators as does 
Barclays - 8 vs. 4 in their 2007 reports (Citigroup, 2008b; Barclays, 2008c); this difference increases in their 
sustainability reports for 2008, with Citi reporting on nine of the core environmental performance indicators while 
Barclays discloses information on only three (Citigroup, 2009; Barclays, 2009). On the other hand, there is no 
apparent difference in the emphasis that the companies place on Labor Practices & Decent Work in the narratives of 
their respective reports. Consequently, it is curious that Barclays reports on eight of the core indicators in that area 
(dropping to six indicators in its 2008 report) while Citi only provides information on three (dropping to two in its 
2008 report). There does not seem to be anything particularly unusual about the indicators on which Barclays reports 
but Citi does not [viz. LA1: Total workforce by employment type, employment contract, and region; LA2: Total 
number and rate of employee turnover by age group, gender, and region; LA3: Benefits provided to full-time 
employees that are not provided to temporary or part-time employees; LA5: Minimum notice period(s) regarding 
operational chances; LA7: Rates of injury, occupational diseases, lost days, and absenteeism, and number of 
workforce fatalities by region; LA14: Ratio of basic salary of men to women by employee category] which would 
explain the discrepancy. Another interesting difference is that Barclays provides information on three core indicators 
in 2008 (two in 2009) in the area of human rights which Citi reports as being non-material to its operations. This 
additional disclosure may be more a function of Barclays leadership role in human rights initiatives (e.g. it is one of 
14 corporations which form the Business Leaders Initiative on Human Rights) than it is a reflection of Citi’s 
understatement of the impact on human rights in its business (Barclays, 2008c).  
 
Merck vs. Bayer 
 
The primary difficulty in comparing the Merck and Bayer reports does not stem so much from the different 
level of reporting chosen by the companies (Merck at the B level; Bayer at the A+ level) as from the different units 
of measures used. Indeed, Merck’s reporting of 82% in 2007, increasing to 86% in 2009, of the core performance 
indicators was only slightly lower than Ford’s at 84% and was higher than the 78% reported by VW in their first G3 
reports – and this in spite of the fact that the two car companies report at the A level (Bayer, 2008a; Merck, 2007a). 
Moreover, the two pharmaceutical companies have 80% common performance indicators in their first reports. This 
increases to 84% for their second iteration of G3 reports (Bayer, 2010; Merck, 2008a).  
 
As just one example of the different units of measure, Bayer reports that its total energy use in 2007 was 
91.7 petajoules (equivalent to 25.5 terawatt hours) in 2007; Merck reports its 2007 energy use as 15.2 million BTU x 
10
6
 (Bayer, 2008g; Merck, 2007a). The information about energy usage is indeed being disclosed by both companies 
but is it comparable?  
 
Because of the generally greater disclosure by these pharmaceutical companies, a closer look at the actual 
information being disclosed by other companies in the industry is warranted in a later section of this paper. 
 
Nike vs. Adidas 
 
From a corporate responsibility perspective, perhaps the greatest challenge for Nike, Adidas, and the global 
sporting goods and apparel industry is the management of their supply chain. The companies do not manufacturer 
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the shoes, apparel, and equipment they sell under their brand-name. Instead the manufacturing of their products is 
subcontracted to factories, most of which are located in developing nations. Nike, for example, has only around 
24,000 employees, the vast majority working in the United States. All other workers are employed by its 
independent suppliers. Nike estimates that of the 800,000 workers in its contract supply chain, 80% are women 
between the ages of 18 and 24 (Nike, 2007a, p. 16). Adidas has a very similar, if somewhat more geographically 
dispersed organizational structure (over 31,000 employees in 150 locations (Adidas, 2008a, p. 56)).  Because they 
face the same corporate citizenship challenges, one would expect the companies’ sustainability reports to provide a 
similar approach and similar information to communicate their efforts.  Yet an analysis of the content of the two 
reports reveals disturbing inconsistencies in the way in which economic, social, and environmental performance is 
disclosed. The “footprint” (i.e., locations) of the companies suppliers is remarkably similar (Adidas, 2008a, p. 62-
63; Nike, 2007a, p. 25) yet the metrics used to measure performance are non-comparable. For example, Adidas has 
created a KPI (Key Performance Indicator) consisting of six units of measure (Adidas, 2008a, p. 36). While the 
company reports the average score in each of the units of measure, there is no way to interpret these data. Nike has a 
seemingly similar system of auditing the compliance of its suppliers with company policies but it reports the results 
of this compliance in very different terms than does Adidas (Nike, 2007a, pp. 30-32). In short, there is no way to 
conclude which company is doing a better job of managing its supply chain. Rather than presenting common 
denominators for comparison of the two companies’ economic, environmental, and social performance, the disparity 
in the amounts and types of core performance indicators presented by Nike and Adidas make any comparison 
between the two companies meaningless.  
 
It would be in precisely this situation that one would hope that use of the G3guidelines would promote 
greater comparability.  However, in their first G3 reports, disclosure on the 50 core performance indicators is 
minimal. Nike reported on about half (48%); Adidas on only 18% (Nike, 2007b; Adidas Group, 2008b). Perhaps as 
disappointing is the companies reported on only 28% of common performance indicators.  In its most recent 
sustainability report, Adidas no longer uses the G3 guidelines (Adidas Group, 2010). Given the paucity of reported 
core performance indicators when Adidas was using the guidelines, there seems to be little loss since comparability 
with Nike’s performance was so minimal.  
 
A Closer Look at the Pharmaceutical Companies 
 
In order to further investigate the comparability of the G3 reports, this study takes a closer look at the 
actual data reported by companies in the pharmaceutical industry. Table 4 lists twenty of the fifty core indicators 
which were deemed to be the most objective and quantifiable. Table 5 lists the thirteen well-known pharmaceutical 
companies analyzed. It should be noted that 10 of these companies use the G3 Guidelines. Three companies – 
Abbott, Johnson & Johnson, and sanofi-aventis – do not actually prepare G3 reports but do reference the G3 and use 
the core performance indicators which they felt are most relevant to their operations. Given the commonality of the 
indicators disclosed, these companies were included in the sample despite the absence of formal implementation of 
the G3 Guidelines. 
 
A first level of comparability between and among these companies is represented by the common 
disclosures contained in their reports. Table 6 provides an overview of this comparability.  For instance, all thirteen 
companies report on core indicators EC2 (financial implications and other risks and opportunities for the 
organization’s activities due to climate change), EN3 (direct energy consumption by primary energy source), and 
EN16 (total direct and indirect greenhouse gas emissions by weight).There is also comparability in the disclosures 
that are “under-reported” by the companies. For example, only 38% of the companies provide information on EN2 
(percentage of materials used that are recycled input materials) or LA2 (total number and rate of employee turnover 
by age group, gender, and region); only 23% of the pharmaceutical companies analyzed disclose information on 
LA14 (ratio of basic salary of men to women by employee category).  Remembering that these indicators are 
considered “core” because the GRI believes them to be of interest to most stakeholders and, consequently, they are 
“assumed to be material unless deemed otherwise on the basis of the GRI Reporting Principles” (GRI, 2006), this 
non-reporting is somewhat surprising. 
 
A second level of comparability is represented by the actual data being disclosed by the companies for each 
of the performance indicators. This analysis now looks at the information that is being reported for six of the core 
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performance indicators – one in each of the major TBL categories. 
 
Economic 
 
EC1: Direct economic value-generated and distributed, including revenues, operating costs, employee 
compensation, donations and other community investments, retained earnings and payments to capital providers 
and customers 
 
As noted in Table 6, 92% of the companies selected for this study disclose information on EC1with sanofi-
aventis being the only company that does not report on this core performance indicator. However, how this 
information is disclosed is not the same for the other 12 companies. AstraZeneca (2008d) and Roche (2009b) merely 
reference their annual 10-K for information on this indicator; GlaxoSmithKline (2008c) and Pfizer (2008e) do not 
provide any concrete objective information. The remaining eight companies list fairly comparable information. All 
report information regarding their annual revenue figures. The disparity in the disclosure comes from what else is 
reported: 
 
 Disclosure regarding employee compensation is covered in the G3 Reports of Abbott (2008a), Novartis 
(2008b), and Novo Nordisk (2009g).  
 Disclosure regarding charitable contributions and philanthropy is included in the G3 reports of Abbott 
(2008a; 2008b), Baxter (2008b) and Johnson & Johnson (2008b). 
 Disclosure regarding dividend and shareholder information is reported by Abbott (2008a), Baxter (2008b), 
Johnson & Johnson (2008b), Merck (2008b), Novartis (2008b) and Novo Nordisk (2008g). 
 
Other items reported under EC1 by Baxter (2008b), Johnson & Johnson (2008b), Merck (2008b), Novartis 
(2008b) and Novo Nordisk (2008g) include the amount of value added to the government in the form of taxes. In 
addition, the reports of Bayer (2008b) and Merck (2008b) include information on how many are employed within 
the company, and Bristol-Myers Squibb (2008b) discloses the total number of its suppliers.  
 
Environmental 
 
EN28: Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with 
environmental laws and regulations 
 
Of the companies studied for further analysis, twelve of the thirteen companies reported information on 
EN28, with sanofi-aventis again being the only company not to disclose. Two of the companies, Abbott (2008a) and 
Bayer (2008g), reference the note regarding litigation in their Annual 10-Ks. Novo Nordisk (2009c) does not have 
an objective or quantifiable disclosure; instead, the company states that they will only report on noncompliance with 
environmental regulations, but on nothing that is not a legal issue. The remaining companies do disclose some 
information. Pfizer (2008c) and Roche (2009c) both report that there were no fines imposed for the most recent 
reporting year. Novartis disclosed the amount of fines it paid. The disclosure of the fines is the only place where 
comparability exists among all of the companies. There is a disparity among the companies in reference to which 
type of sanctions are reported. Baxter (2008d) discloses information regarding their number of violations for the past 
two years, as well as their environmental fines and environmental incidents over the span of 2005-2008. 
GlaxoSmithKline (2008b) and Merck (2008c) both provide information on the number of inspections performed; 
however, Merck goes further with releasing the amount of spills, safety notices, and violations of environmental 
matters.  
 
Social: Society 
 
SO1: Nature, scope, and effectiveness of any programs and practices that assess and manage the impacts of 
operations on communities, including entering, operating, and exiting 
 
Sixty-nine percent (9 of the 13) of the companies disclose information on SO1. This is the performance 
indicator in which each company reports information that is relevant and important to their place in society. Because 
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of this, it would be expected that the companies in this sample utilize this indicator in a variety of different ways. 
Roche (2009g) uses this indicator to disclose its continued philanthropic efforts. For GlaxoSmithKline (2008i), this 
indicator allows the company to disclose their contribution to the global health community. For sanofi-aventis 
(2008e), this disclosure creates an opportunity for further discussion in its research and development. Given the 
widely differing uses of this performance indicator, while the information may not be comparable on the basis of 
objectivity, it is comparable in the sense that it represents the goals and values of each company. 
 
Social: Human Rights 
 
HR2: Percentage of significant suppliers that have undergone screening on human rights and actions taken 
 
Twelve of the thirteen (ninety-two percent) of the analyzed companies provide disclosures on HR2. The 
main purpose of this indicator is to show a percentage; however, for most the companies, the disclosure did not 
provide a very quantifiable number. Merck, Novartis and Novo Nordisk are the three companies which provided the 
most objective disclosures. Merck (2008d) includes information on the standards that their suppliers are expected to 
follow, as well as the surveys, including details on ethical, health and labor standards, that are sent to each of their 
suppliers. In 2008, 81% of their suppliers completed this survey, and in 2007, 54% complete this survey. Novartis 
(2008d) notes their number of significant suppliers (416, which represents 31%) as the answer to the percentage that 
has undergone screening. Novo Nordisk (2009d) includes information about the consistency of the audits of their 
suppliers, and discloses that in 2009, 20 audits were performed, resulting in a number of critical findings. Many of 
the other companies have established that there are specific guidelines for the suppliers. For instance, Abbott 
(2008h) has Supplier Guidelines which emphasize the importance of fair competition and ethical working standards; 
it also discloses information regarding the amount of their suppliers owned by minorities, women and small-
businesses. Bayer (2008f) enforces the Bayer Procurement Community Policy for its suppliers. Baxter (2008f) has 
quality and compliance standards with a focus on child labor, confidential and proprietary information, fair 
employment, and intellectual property. Baxter also assesses their suppliers for their sustainability programs. 
GlaxoSmithKline (2008h) and sanofi-aventis (2008b) both state that their suppliers are audited and evaluated. 
Johnson & Johnson (2008d) places emphasis on global labor and child labor, and focuses on supplier diversity. Only 
one company - Bristol-MyersSquibb - does not report on HR2 with Roche (2009h) referring to the Annual Business 
Report for information regarding this disclosure.  
 
Social: Labor Practices & Decent Work 
 
LA1: Total workforce by employment type, employment contract, and region 
 
Of the eight companies that disclose statistics for LA1, six report in a very similar objective and 
quantifiable fashion. Of these six, all but one (Roche, 2009e) disclose information regarding the regional headcount. 
For example, Baxter (2008c), Bayer (2008d), and sanofi-aventis (2008c) list at least two years of data, broken out by 
the regions in which the company operates. Novartis (2008e) and Novo Nordisk (2009b) disclose the employee 
headcount for only 2009. Abbott (2008b) and Merck (2008e) are the two companies who disclose information on 
LA1, but are not comparable with the other companies. Abbott places their emphasis on having a diverse workforce, 
but does not provide any evidentiary support. Merck lists statistics regarding the number of women and ethnics 
groups that are employed, but nothing further. 
 
Social: Product Responsibility 
 
PR1: Life cycle stages in which health and safety impacts of products and services are assessed for improvement, 
and percentage of significant products and service categories subject to such procedures 
 
All but one of the companies studied (Bristol-MyersSquibb) report on PR1. For a great majority of the 
companies who report on this indicator, product and patient safety are the main concern and are of greatest 
importance. Abbott (2008c), AstraZeneca (2008g), and Pfizer (2008f) report that they have an increased focus on 
research and development leading to a safe product. Bayer (2008j) lists responsible marketing as one of its tools to 
ensure product and patient safety.  Instead of just focusing on the marketing aspect, some companies focus on the 
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entire life cycle. For instance, Abbott (2008c) places heavy emphasis on assessing the regulation, manufacturing, 
and sales, marketing and distribution. Baxter (2008g) performs a two-step assessment, one high level and one 
comprehensive, across its products’ life cycle. Roche (2009f) focuses on the promotion of patient safety throughout 
its supply chain. GlaxoSmithKline (2008e; 2008g; 2008j) performs audits of suppliers and works on anti-
counterfeiting methods. Johnson & Johnson (2008e) perform evaluations from the level of the raw materials to 
ensure a safe product. Novartis (2008f) uses two methods – clinical trials and pharmacovigilance – to produce safe 
products. Novo Nordisk (2009e) discloses their focus on compliance with regulation and global standards, and also 
emphasizes the performance of audits and anti-counterfeiting methods. 
 
A couple of the companies under study take a completely different route when disclosing on this indicator. 
For example, Merck (2008f) focuses on the safety in the workplace by listing a decrease in the lost-time rate. Sanofi-
aventis (2008d) includes information about its commitment to reduce the environmental impact for the entire life 
cycle of the drug, with optimization of packaging as its focal point. 
 
CONCLUSION 
 
One of the objectives of this study is to see how the sustainability reports using the G3 Guidelines evolve 
over successive iterations. Table 1 gives an overview of these companies originally studied by Sherman (2009). The 
rationale for permitting varying levels of reporting is to give organizations an opportunity to experiment with using 
the G3 indicators without having to adopt them all at once. The hope is that companies will increase their level of 
reporting over time. With the possible exception of Nike (which did not state the reporting level of its 2007 G3 
report), no company has increased its level of reporting. Adidas, on the other hand, no longer uses the G3 Guidelines 
at all. Nevertheless, even with no change in reporting levels, there was a general increase in the number of core 
performance indicators for which information is provided in the companies’ second G3 reports relative to their first 
G3 reports. Adidas and Barclays are the two companies which report on fewer indicators the second time around. 
Table 3 summarizes these changes.  
 
A growing trend in sustainability reporting is external verification of the reports (KPMG, 2008). However, 
among this limited sample, only Volkswagen, Barclays, and Bayer had external verified first reports. This did not 
change in the second iterations. A slightly higher proportion of the pharmaceutical companies studied (6 out of 13) 
opted for external verification of their sustainability reports.  
 
A logical conclusion to reach is that by reporting on more of the core performance indicators (see Table 3) 
and by having a greater commonality in the indicators for which information is disclosed (see Table 2), 
comparability of sustainability reports is enhanced. However, as noted in the analysis of the individual pairs of 
companies, there is a disturbing lack of common measures of reporting the 50 core indicators. In order to address 
this issue, this analysis was extended to an expanded number of companies in a particular industry. More 
importantly, this study looks at the data behind the disclosures. 
 
To further analyze the companies in the pharmaceutical industry, indicators that were expected to be the 
most quantifiable and objective were selected. An analysis of a sample of twenty core performance indicators leads 
to the conclusion that comparability of the information being disclosed varies significantly. For some indicators, the 
information reported is indeed comparable. However, this is certainly not the case for all of the indicators. In some 
cases, the units of measures pose an impediment to comparability. For example, while all of the selected 
pharmaceutical companies disclose information on EN3 (direct energy consumption by primary energy source), 
there is a lack of consistency in how this information is expressed in the reports. A variety of different units of 
measure are used by the companies. Four of the thirteen companies use “million gigajoules” as their unit of measure. 
Other units of measure employed include terajoules (Roche, 2009a)), petajoules (Bayer, 2008i), or gigajoules 
(sanofi-aventis, 2008a).  
 
While the lack of comparability for some of the indicators can be remedied with a relatively simple 
conversion, for others, there is no easy fix. The information is simply not being disclosed in an objective and 
quantifiable fashion. This lack of objectivity is most noticeable in the social indicators, particularly in those related 
to Society and Human Rights.  Because these are areas of TBL reporting in which each company reports information 
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it believes is most relevant and important to its place in society, it is not surprising that the data presented are not 
comparable.  
 
It has been the hope that with the further development and use of the G3 Guidelines, there would be an 
increased comparability among the sustainability reports of the companies using these guidelines. However, despite 
the fact that these companies are all within the pharmaceutical industry and, therefore, face similar challenges to 
their corporate citizenship, comparability among reports has not been fully enhanced by the GRI’s core performance 
indicators. Moreover, there will probably always be difficulty of interpreting core performance indicators even when 
they are consistently disclosed. As one survey of sustainability reports concludes:  
 
At the same time, the problem may arise from the lack of an established means of assessing sustainability 
information in reports. It might then be said that the reports provide “too much information, too little meaning” 
(KPMG & SustainAbility, 2008, p. 29). 
 
Is TBL reporting becoming more comparable? This study has been unable to answer that question 
definitively. While the G3 Guidelines do provide a common basis for reporting, there is still a long way to go before 
the equivalent of GAAP for sustainability reporting is established.  
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Table 1: Reporting level & verification 
 Application GRI Content  
Company Level Verification Country Industry 
Ford Motor Company A Self-declared USA Automotive 
Volkswagen  A+ GRI-checked Germany Automotive 
 
Barclays B+ Third-party-checked UK Financial Services 
Citigroup B Self-declared USA Financial Services 
 
Bayer AG A+ GRI-checked Germany Pharmaceuticals 
Merck & Co B GRI-checked USA Pharmaceuticals 
 
Adidas Group C in 2006 Self-declared Germany Sporting Goods 
 None in 2009    
Nike NA in 2006 Self-declared USA Sporting Goods 
 B in 2009    
 
 
Table 2: Common Core Indicators Reported 
 2006-07 2008-09 
Ford vs. Volkswagen: 70% 82% 
Citigroup vs. Barclays: 26% 20% 
Merck vs. Bayer: 80% 84% 
Nike vs. Adidas: 28% 0% 
Note: Even with common indicators, the units of measurement used frequently varies between companies 
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Table 3: G3 Core Performance Indicators Disclosed 
Economic 
Ford 
2006-07 
Ford 
2008-09 Change 
VW 
2006-07 
VW 
2008-09 Change 
Citigroup 
2006-07 
Citigroup 
2008-09 Change 
Barclays 
2006-07 
Barclays 
2008-09 Change 
Total 5 6 1 5 6 1 5 5 0 6 6 0 
% 71.43% 85.71% 14.29% 71.43% 85.71% 14.29% 71.43% 71.43% 0.00% 85.71% 85.71% 0.00% 
Environmental            
Total 16 16 0 12 15 3 8 9 1 4 3 -1 
% 94.12% 94.12% 0.00% 70.59% 88.24% 17.65% 47.06% 52.94% 5.88% 23.53% 17.65% -5.88% 
Social: Labor Practices and Decent Work          
Total 7 8 1 8 9 1 3 2 -1 8 6 -2 
% 70.00% 80.00% 10.00% 80.00% 90.00% 10.00% 30.00% 20.00% -10.00% 80.00% 60.00% -20.00% 
Social: Human Rights            
Total 6 6 0 6 6 0 0 0 0 3 2 3 
% 100.00% 100.00% 0.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 50.00% 33.33% -16.67% 
Social: Society      NM      
Total 6 6 0 5 6 1 4 4 0 4 3 -1 
% 100.00% 100.00% 0.00% 83.33% 100.00% 16.67% 66.67% 66.67% 0.00% 66.67% 50.00% -16.67% 
Social: Product Responsibility           
Total 2 3 1 3 3 0 0 0 0 0 0 0 
% 50.00% 75.00% 25.00% 75.00% 75.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 
Totals             
50 42 45 3 39 45 6 20 20 0 25 20 -5 
 84.00% 90.00% 6.00% 78.00% 90.00% 12.00% 40.00% 40.00% 0.00% 50.00% 40.00% -10.00% 
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Table 3: G3 Core Performance Indicators Disclosed (Continued) 
Economic 
Merck 
2006-07 
Merck 
2008-09 Change 
Bayer  
2006-07 
Bayer 
2008-09 Change 
Nike 
2006-07 
Nike 
2008-09 Change 
Adidas 
2006-07 
Adidas 
2008-09 Change 
Total 5 6 1 7 7 0 4 4 0 1 0 -1 
% 71.43% 85.71% 14.29% 100.00% 100.00% 0.00% 57.14% 57.14% 0.00% 14.29% 0.00% -14.29% 
Environmental            
Total 12 14 2 17 17 0 8 10 2 2 0 -2 
% 70.59% 82.35% 11.76% 100.00% 100.00% 0.00% 47.06% 58.82% 11.76% 11.76% 0.00% -11.76% 
Social: Labor Practices and Decent Work          
Total 9 8 -1 9 9 0 3 3 0 1 0 -1 
% 90.00% 80.00% -10.00% 90.00% 90.00% 0.00% 30.00% 30.00% 0.00% 10.00% 0.00% -10.00% 
Social: Human Rights            
Total 5 5 0 6 6 0 6 6 0 4 0 -4 
% 83.33% 83.33% 0.00% 100.00% 100.00% 0.00% 100.00% 100.00% 0.00% 66.67% 0.00% -66.67% 
Social: Society            
Total 6 6 0 6 6 0 2 2 0 0 0 0 
% 100.00% 100.00% 0.00% 100.00% 100.00% 0.00% 33.33% 33.33% 0.00% 0.00% 0.00% 0.00% 
Social: Product Responsibility           
Total 4 4 0 4 4 0 1 1 0 1 0 -1 
% 100.00% 100.00% 0.00% 100.00% 100.00% 0.00% 25.00% 25.00% 0.00% 25.00% 0.00% -25.00% 
Totals             
50 41 43 2 49 49 0 24 26 2 9 0 -9 
 82.00% 86.00% 4.00% 98.00% 98.00% 0.00% 48.00% 52.00% 4.00% 18.00% 0.00% -18.00% 
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Table 4: GRI Core Performance Indicators – A Sample 
Economic 
 *EC1: Direct economic value-generated and distributed, including revenues, operating costs, employee 
compensation, donations and other community investments, retained earnings and payments to capital 
providers and customers 
 EC2: Financial implications and other risks and opportunities for the organization’s activities due to climate change 
 
Environmental 
 EN1: Materials used by weight or volume 
 EN2: Percentage of materials used that are recycled input materials 
 EN3: Direct energy consumption by primary energy source 
 EN4: Indirect energy consumption by primary source 
 EN16: Total direct and indirect greenhouse gas emissions by weight 
 *EN28: Monetary value of significant fines and total number of non-monetary sanctions for non-compliance 
with environmental laws and regulations 
 
Society 
 *SO1: Nature, scope, and effectiveness of any programs and practices that assess and manage the impacts of 
operations on communities, including entering, operating, and exiting 
 SO4: Actions taken in response to incidents of corruption 
 SO8: Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with laws 
and regulations 
 
Human Rights 
 HR1: Percentage and total number of significant investment agreements that include human rights clauses or that have 
undergone human rights screening 
 *HR2: Percentage of significant suppliers that have undergone screening on human rights and actions taken 
 HR4: Total number of incidents of discrimination and actions taken 
 
Labor Practices & Decent Work 
 *LA1: Total workforce by employment type, employment contract, and region 
 LA2: Total number and rate of employee turnover by age group, gender, and region 
 LA 10: Average hours of training per year per employee by employee category 
 LA14: Ratio of basic salary of men to women by employee category 
 
Product Responsibility 
 *PR1: Life cycle stages in which health and safety impacts of products and services are assessed for 
improvement, and percentage of significant products and service categories subject to such procedures 
 PR9: Monetary value of significant fines for noncompliance with laws and regulations concerning the provision and 
use of products and services 
* Selected for further analysis 
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Table 5: Selected Pharmaceutical Companies 
Company Adherence Level Verification Country 
Abbott Undeclared1 N/A USA 
Astra Zeneca B+ Third-party-checked UK 
Baxter B Self-Declared USA 
Bayer AG A+ GRI-checked Germany 
Bristol-Myers Squibb Company A Third-party-checked UK 
GlaxoSmithKline A+ Self-Declared UK 
Johnson & Johnson Undeclared2 N/A USA 
Merck and Co. B GRI-checked USA 
Novartis A+ GRI-checked Switzerland 
Novo Nordisk A+ Self-Declared Denmark 
Pfizer B Self-Declared USA 
Roche A+ GRI-checked Switzerland 
Sanofi-Aventis Undeclared3 N/A France 
 
 
Table 6: Comparability of G3 Reports in Pharmaceutical Industry on Selected Indicators 
 
Fully 
Reported 
Partially 
Reported 
Not 
Reported % Reported % Not Reported 
Economic      
EC1 12 0 1 92% 8% 
EC2 13 0 0 100% 0% 
Environmental      
EN1 7 0 6 54% 46% 
EN2 5 0 8 38% 62% 
EN3 13 0 0 100% 0% 
EN4 10 1 2 85% 15% 
EN16 13 0 0 100% 0% 
EN28 12 0 1 92% 8% 
Social: Labor Practices and Decent Work     
LA1 7 1 5 62% 38% 
LA2 2 3 8 38% 62% 
LA10 6 1 6 54% 46% 
LA14 0 3 10 23% 77% 
Social: Human Rights       
HR1 5 1 7 46% 54% 
HR2 11 1 1 92% 8% 
HR4 5 1 7 46% 54% 
Social: Society      
SO1 8 1 4 69% 31% 
SO4 8 0 5 62% 38% 
SO8 8 0 5 62% 38% 
Social: Product Responsibility     
PR1 12 0 1 92% 8% 
PR9 7 0 6 54% 46% 
  
 
 
                                                          
1 Abbott has not adopted the G3 Guidelines. Instead, its report “refers” the G3 Guidelines and provides its own index which it 
compares against the GRI Guidelines. 
http://www.abbott.com/global/url/content/en_US/40.10.40:40/general_content/General_Content_00053.htm. 
2 J & J has not adopted the G3 Guidelines. However, “consideration was given” to the G3 Guidelines and “an index with 
references to G3 indicators” is included in its report. http://www.myvirtualpaper.com/doc/jnj/JnJ_2008/2009060901/ . 
3 sanofi-aventis’ sustainability report is “designed according to the Global Reporting Initiative (GRI) 3 Guidelines” and reports 
on some of the indicators the company feels are most relevant.  
http://en.sanofi-aventis.com/binaries/RDD_2008_EN_tcm28-24844.pdf. 
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NOTES 
